Synapse - Advanced Practice Providers

Results (78)

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma—Safety and outcomes

Journal Article

Sait, S. F.; Kernan, N. A.; Klein, E.; Spitzer, B.; Levy, C. F.; Fish, J.; Yildirim, O.; Haque, S.; Donzelli, M.; Bernot, M. R.; more...
Pediatric Blood and Cancer (2024)

Fulltext@MSK | Save

Theranostic intratumoral convection-enhanced delivery of (124)I-omburtamab in patients with diffuse intrinsic pontine glioma: Pharmacokinetics and lesion dosimetry

Journal Article

Pandit-Taskar, N.; Zanzonico, P. B.; Grkovski, M.; Donzelli, M.; Vietri, S. M.; Horan, C.; Serencsits, B.; Prasad, K.; Lyashchenko, S.; Kramer, K.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with (131)I-omburtamab for leptomeningeal disease

Journal Article

Prasad, K.; Serencsits, B. E.; Chu, B. P.; Dauer, L. T.; Donzelli, M.; Basu, E.; Kramer, K.; Pandit-Taskar, N.
EJNMMI Research (2024)

Fulltext@MSK | Save

Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma

Meeting Abstract

Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
Blood (2023)

Fulltext@MSK | Save

PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma

Meeting Abstract

Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma

Meeting Abstract

Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save